Novi Technology (Beijing)

Founded in April 2014, Novi Technology (Beijing) Co., Ltd. is a biopharmaceutical company focused on developing innovative drugs, particularly next-generation anti-tumor DNA vaccines. The company leverages scientific research from Peking University and Tsinghua University to drive its biotechnology R&D and industrial application efforts. In 2017, it was recognized as both a National High-tech Enterprise and a Zhongguancun High-tech Enterprise.

The firm operates two main technology platforms: STARi (Super Targeting Activated Response of immunization) for creating various tumor vaccine products, and the NewishT cell therapy platform. A key product from the NewishT platform is an autologous memory lymphocyte injection, which was the first cell therapy product primarily composed of central memory T cells to be approved by national drug regulators for preventing recurrence after solid tumor surgery. Novi Technology has also developed DNA vaccines for liver cancer and HPV, with its HPV therapeutic DNA nucleic acid drug, NWRD08, entering the IND application phase with China's National Medical Products Administration (NMPA).

The company is led by CEO Dr. Liu Defang and co-founder and CTO Dr. Qi Hailong. Novi has established a B+A level GMP pilot plant for new drugs and a DNA tumor vaccine research and development laboratory in the Beijing Economic and Technological Development Zone. Its business model revolves around the R&D of first-in-class gene therapy and immunotherapy drugs with fully independent intellectual property rights, aiming to address unmet clinical needs in early-stage tumor treatment. The company has successfully raised capital, including a Pre-B round of 50 million yuan.

Keywords: anti-tumor DNA vaccines, immunotherapy, cell therapy, oncology, biopharmaceutical, NewishT, STARi platform, gene therapy, liver cancer, HPV, clinical trials, biotechnology, cancer treatment, drug development, NWRD08, nucleic acid drugs, central memory T cells, tumor recurrence prevention, first-in-class drugs, Beijing Economic and Technological Development Zone